Relypsa seeks FDA nod for patiromer to treat hyperkalemia
This article was originally published in Scrip
Executive Summary
Redwood City, California-based Relypsa is seeking the FDA's blessing to market patiromer for oral suspension as a treatment for hyperkalemia, a serious condition defined as abnormally elevated levels of potassium in the blood.